{"id":"W2745671375","doi":"10.1200/jco.2017.35.15_suppl.3063","title":"Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAF<sup>V600</sup>-mutant metastatic melanoma (mel): Updated safety and clinical activity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Vemurafenib; Maculopapular rash; Rash; Nausea; Internal medicine; Melanoma; Atezolizumab; CD8; Adverse effect; Oncology; Gastroenterology; Metastatic melanoma; Pharmacology; Nivolumab; Cancer; Cancer research; Immune system; Immunotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006670812,0.0003195019,0.00197781,0.0001153181,0.0001908259,0.00006350892,0.0008040081,0.0008466874,0.00008756107],"category_scores_gemma":[0.006217684,0.0002537857,0.0006180151,0.00006851315,0.0007180573,0.00004190162,0.000466907,0.001244498,0.00002430046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005176176,"about_ca_system_score_gemma":0.001282478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005857367,"about_ca_topic_score_gemma":0.0002928482,"domain_scores_codex":[0.9938769,0.001581673,0.003162074,0.0005784588,0.0003076083,0.0004932649],"domain_scores_gemma":[0.9942828,0.0009931212,0.003095157,0.0007787474,0.0002836918,0.000566515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03244682,0.00524861,0.2631904,0.00007370878,0.002266815,0.003984232,0.000176239,0.00009223404,0.02231605,0.0006151269,0.004862514,0.6647272],"study_design_scores_gemma":[0.02458273,0.02036208,0.5635563,0.00009318643,0.0004839772,0.001220905,0.000131943,0.0007728189,0.003852855,0.0004348518,0.3839253,0.0005831188],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919848,0.0003596644,0.0002518784,0.002277845,0.001128272,0.000277074,0.00003550624,0.000006815277,0.003678072],"genre_scores_gemma":[0.9935062,0.002491847,0.001712694,0.0007027674,0.001160684,0.000003689039,0.00002043055,0.00003573802,0.0003659453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6641441,"threshold_uncertainty_score":0.9999914,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08158401592202198,"score_gpt":0.4247040565933026,"score_spread":0.3431200406712806,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}